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　 Non-alcoholic steatohepatitis (NASH) is correlated with metabolic syndrome, and the prevalence of 
NASH patients is increasing worldwide.  Fast food is considered a risk for the pathogenesis of NASH, so 
dietary therapy is very important for its prevention.
　 In this study, amino acid composition of rat liver of NASH model was examined.  WKY male rats (6 
weeks old) were randomly divided into 8 groups.  Control groups were fed control diets for 4 weeks, 8 
weeks, 12 weeks and 16 weeks, respectively.  HFC groups were fed high fat and high cholesterol diet for 4 
weeks, 8 weeks, 12 weeks and 16 weeks, respectively.  The liver weight of HFC group was high compared 
with control rat, and the surface color was whitish, indicating deposition of much lipid in the HFC liver.
　 The cell pathology of liver was examined by transmission electron microscopy.  Many lipid droplets 
were observed in the cytoplasm of hepatocyte, which increased after 8 week-intake of HFC diet.
　 Amino acid analysis showed the increase of hydroxyproline in the liver of HFC group, while the other 
amino acids were decreased.  Because hydroxyproline is a chief component of collagen molecules, the 
deposition of collagen fibrils in NASH liver has been confirmed by amino acid analysis.











































































エネルギー （kcal） 373 460
タンパク質 （g） 20.8 14.7
脂質 （g） 2.8 28.6
炭水化物 （g） 66.1 31.3
コレステロール （g） Tr 5.0





ル群間（Cont4w vs Cont8w vs Cont12w vs 
Cont16w）または高脂肪・高コレステロール群間






































4w Cont 303.6 ± 1.66 10.7 ± 0.30 3.5 ± 0.11
HFC 272.9 ± 18.86 15.9 ± 1.00** 5.8 ± 0.05**
8w Cont 349.8 ± 10.37† 11.3 ± 0.26 3.2 ± 0.25†
HFC 310.0 ± 17.07* 28.6 ± 1.35**
¶ 9.3 ± 0.97**
12w Cont 415.5 ± 13.46†,‡ 12.8 ± 0.19†,‡ 3.1 ± 0.12
HFC 347.7 ± 13.60**
¶ 30.6 ± 1.06**
¶ 8.8 ± 0.89**
16w Cont 432.0 ± 13.75†,‡ 12.4 ± 0.80† 2.9 ± 0.10†,‡
HFC 362.6 ± 0.97¶*
,‖ 39.7 ± 2.28**

























































A, Cont4w; B, HFC4w; C, Cont8w; D, HFC8w















































 4w 8w 12w 16w
（μg/g） Cont HFC Cont HFC Cont HFC Cont HFC
Hypro 0.092±0.02 0.072±0.02 0.223±0.04 0.251±0.05 0.096±0.02 0.151±0.00 0.052±0.03 0.146±0.04*
Asp 3.950±0.38 2.682±0.24** 4.560±0.40 2.532±0.11** 3.467±0.25‡ 2.396±0.06* 3.469±0.48‡ 2.388±0.10*
Thr 2.105±0.22 1.402±0.12** 2.435±0.23 1.335±0.05** 1.830±0.13‡ 1.261±0.03** 1.826±0.27‡ 1.248±0.06*
Ser 2.019±0.22 1.375±0.12* 2.305±0.21 1.306±0.05** 1.717±0.13‡ 1.235±0.04** 1.682±0.25‡ 1.229±0.04*
Glu 5.740±0.63 3.959±0.32* 6.310±0.48 3.659±0.13** 5.009±0.32‡ 3.514±0.09** 4.839±0.50‡ 3.669±0.14*
Pro 1.889±0.19 1.233±0.11** 2.319±0.19 1.252±0.05** 1.708±0.13‡ 1.192±0.02** 1.769±0.28‡ 1.267±0.05
Gly 2.213±0.22 1.469±0.13** 2.621±0.23 1.384±0.06** 2.035±0.16 1.412±0.04** 2.007±0.29‡ 1.519±0.05
Ala 2.535±0.24 1.650±0.14** 3.050±0.28 1.550±0.09** 2.243±0.16‡ 1.457±0.03 2.230±0.32‡ 1.463±0.07*
Cys 0.347±0.03 0.270±0.03* 0.431±0.07 0.358±0.02¶ 0.431±0.03 0.358±0.01¶ 0.473±0.09 0.362±0.04¶
Val 2.378±0.25 1.611±0.13** 2.967±0.26 1.571±0.07** 2.202±0.16‡ 1.454±0.04** 2.202±0.34‡ 1.393±0.09*
Met 0.973±0.15 0.313±0.10** 1.417±0.14† 0.737±0.04**
¶ 0.995±0.07‡ 0.472±0.01‖** 1.042±0.18
‡ 0.482±0.08**
‖
Ile 2.081±0.23 1.406±0.10* 2.504±0.25 1.332±0.05** 1.875±0.12‡ 1.256±0.04** 1.877±0.29‡ 1.209±0.08*
¶
Leu 4.362±0.45 2.902±0.26** 5.175±0.48 2.690±0.13** 3.839±0.29‡ 2.526±0.06** 3.847±0.58‡ 2.435±0.15*
¶
Tyr 1.657±0.16 1.003±0.09** 2.151±0.19 1.171±0.04**
¶ 1.521±0.10‡ 1.043±0.03** 1.590±0.28‡ 1.012±0.08*
Phe 2.279±0.22 1.509±0.15** 2.743±0.25 1.419±0.06** 2.073±0.16‡ 1.369±0.04** 2.098±0.32‡ 1.308±0.10*
Hylys 0.095±0.06 0.064±0.01 0.169±0.01 0.145±0.03¶ 0.106±0.03 0.125±0.01¶ 0.116±0.04 0.130±0.01¶
Orn 0.073±0.02 0.053±0.01 0.081±0.01 0.089±0.01 0.069±0.01 0.055±0.00 0.076±0.01 0.055±0.01
Lys 3.245±0.30 2.226±0.20** 3.888±0.33 2.218±0.09** 2.951±0.20‡ 2.031±0.06** 2.962±0.44‡ 2.003±0.12*
His 1.103±0.09 0.778±0.08* 1.342±0.11 0.700±0.03** 1.020±0.08‡ 0.681±0.02** 1.040±0.16‡ 0.658±0.05*
Arg 2.611±0.26 1.734±0.14** 2.986±0.30 1.648±0.08** 2.317±0.17 1.628±0.04* 2.350±0.37 1.665±0.08*
Total 41.653±4.16 27.647±2.47** 49.676±4.43 27.345±1.07** 37.507±2.70‡ 25.617±0.58** 37.545±5.50‡ 25.640±1.29*
データは平均値±標準偏差
*は同じ飼育期間のコントロール群との有意差を示す　*P<0.05　**P<0.01
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